le

An array of health care entities are pressing CMS to revise its proposed prescription drug discount card, claiming it's consortium requirement could expose entities to antitrust violations. The discount card drew more than 40 comments, many of which are listed below.



ts

FOR IMMEDIATE RELEASE:

August 13, 2002

CONTACT:

Beth Porter

(202) 687-4699

bap2@georgetown.edu

INITIALLY RECOMMENDED DRUG DOSAGES OFTEN TOO HIGH, STUDY FINDS



es Click here for CryoLife Press Release

The Food and Drug Administration (FDA) has ordered Cryolife, Inc. ("Cryolife") of Kennesaw, Ga., a human tissue-processing firm, to recall distributed human tissue processed from October 3, 2001, to the present. Under the order, the firm must also withhold from the market or destroy tissue processed after that date.



ds

The Environmental Protection Agency (EPA) took enforcement actions against Mycogen Seeds and Pioneer Hi-Bred International for violating genetically engineered crop laws. The Center For Science in the Public Interest (CSPI) urges EPA to inspect all experimental fields to ensure compliance elsewhere. CSPI - BIO Crops Release CSPI Letter to EPA (PDF format)



/index.php?option=com_iwpfile&file=/dir_01/he2002_2170.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2169.pdf


gs

PhRMA believes that the CMS proposed rule from Aug. 9 will cut Medicare payments to hospitals for a broad range of medicines used in hospital outpatient settings. PhRMA cites smoking cessation products as an example PhRMA Smoking Release PhRMA Outpatient Settings



ts

RESOLUTION Supporting states seeking fair prices for

Prescription drugs and opposing the unwarranted legal actions of the drug companies' lobby, the Pharmaceutical Research and Manufactures of America ("PhRMA") to enjoin continued operation of state initiatives to lower prescription drug prices such as the "Michigan Pharmaceutical Best Practices Initiative".



ts

FDA Statement on the Results of the Women's Health Initiative

Women's Health Initiative (WHI) Results Signal Need for Reassessment of Risks and Benefits of Conjugated Equine Estrogens/medroxyprogesterone Acetate (Prempro) in Postmenopausal Women



/index.php?option=com_iwpfile&file=/dir_01/he2002_2165.pdf


Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.